Swathi Singanamala, MD
Nephrology · Macon, GANPI 1023275617
Payments from drug & device makers
Across 269 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Vifor Pharma, Inc.$579
- Bayer$431
- Daiichi Sankyo Inc.$417
- Otsuka America Pharmaceutical, Inc.$399
- AstraZeneca$362
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,83296%
- Education$2274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 49 | $1,028 |
| Vifor Pharma, Inc. | 30 | $579 |
| Bayer | 26 | $431 |
| Daiichi Sankyo Inc. | 20 | $417 |
| Otsuka America Pharmaceutical, Inc. | 16 | $399 |
| AstraZeneca(2 entities) | 23 | $362 |
| Aurinia Pharma U.S., Inc. | 16 | $297 |
| Akebia Therapeutics Inc | 15 | $255 |
| Travere Therapeutics, Inc. | 27 | $252 |
| Baxter Healthcare | 2 | $160 |
| Fresenius USA Marketing, Inc. | 9 | $149 |
| Novartis | 7 | $142 |
| Ardelyx, Inc. | 5 | $95 |
| GSK | 5 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $81 |
| Calliditas Therapeutics US Inc. | 3 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| OPKO Pharmaceuticals, LLC | 2 | $41 |
| Apellis Pharmaceuticals, Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$5,058 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 23 | $60,126 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $22,861 |
| KerendiaFinerenone | 11 | $21,094 |
| FarxigaDapagliflozin Propanediol | 26 | $19,668 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $16,651 |
| Sevelamer Carbonate | 98 | $13,978 |
| Clonidine | 35 | $3,687 |
| Bumetanide | 122 | $3,132 |
| Midodrine Hcl | 59 | $2,841 |
| Nifedipine ErNifedipine | 99 | $2,766 |
| Calcium Acetate | 38 | $2,385 |
| Losartan Potassium | 217 | $2,268 |
| Potassium Citrate ErPotassium Citrate | 22 | $2,196 |
| Allopurinol | 186 | $2,145 |
| Metoprolol Succinate | 159 | $1,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $255 | $60,12623 claims |
| AstraZenecaFarxiga, Lokelma | $362 | $36,31944 claims |
| BayerKerendia | $431 | $21,09411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.
Other nephrology in Macon
- Sagar PanseMacon$1.1M
- Niraj DesaiMacon$129K
- Carlos MartinezMacon$126K
- Kimathi BlackwoodMacon$64K
- Reuben EllisMacon$27K
- Ahmad KabbaniMacon$16K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.